ArticleFrontiers in oncology2026
Trajectory changes of symptom clusters in patients with concurrent chemoradiotherapy for cervical cancer: a prospective longitudinal study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify the trajectory changes of symptom clusters during concurrent chemoradiotherapy in cervical cancer patients and to explore the heterogeneity of symptom experience among different patients. Methods: From June 2024 to June 2025, 150 patients with cervical cancer undergoing concurrent chemoradiotherapy at a tertiary-level hospital in Anhui Province were selected as the study subjects. A general information questionnaire and the Symptom Assessment Scale for Patients with Intermediate-Advanced Cervical Cancer Undergoing Concurrent Chemoradiotherapy were used to conduct a questionnaire survey at the end of 10 radiotherapy sessions (T1), the end of 20 radiotherapy sessions (T2), the end of radiotherapy (T3), and 3 months after the end of radiotherapy (T4). The Group-based Trajectory Model (GBTM) was used to identify the trajectory changes of symptom clusters during concurrent chemoradiotherapy. Results: This study found that the symptom trajectories during concurrent chemoradiotherapy for cervical cancer could be divided into four categories: low symptom burden group (n=77, 51.33%), moderate symptom burden group (n=16, 10.67%), high symptom burden group (n=36, 24%), and moderate symptom burden - delayed symptom group (n=21, 14%). There were statistically significant differences among the four categories in terms of disease duration, surgical history, and presence of other chronic diseases ( Conclusion: Healthcare professionals should closely monitor symptom changes in cervical cancer patients undergoing concurrent chemoradiotherapy, identify symptom clusters early, and implement individualized and precise symptom management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.